Feedback / Questions
KBA1412 - Kling Bio
https://www.prnewswire.com/news-releases/kling-biotherapeutics-announces-first-patient-dosed-in-phase-1b-clinical-trial-of-kba1412-in-patients-with-advanced-solid-tumors-301636302.html
Sep 29, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next